Press releases

2017-10-26 – Press release

Topas Therapeutics Appoints Rupert Sandbrink, M.D., Ph.D., as Chief Development Officer and Chief Medical Officer

Highly accomplished pharmaceutical executive with many years of clinical development, medical affairs, and regulatory experience at Bayer and Schering
To lead Topas’ clinical development and regulatory affairs

2017-08-22 – Press release

Topas Therapeutics signs multi-year research and option agreement with Lilly focused on immune tolerance

2017-04-04 – Press release

Paul Sekhri joins Topas Therapeutics as Chairman of the Board